FREMONT, CA / ACCESS Newswire / January 6, 2026 / Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in solutions, today announced that President and CEO Gayn Erickso ...
MESA, ARIZONA / ACCESS Newswire / January 5, 2026 / Medical Care Technologies Inc. (OTC Pink:MDCE) announced today that the Company has successfully completed its internal readiness testing phase for ...
YouTube on MSN
Nerf war training!
This is Epic Nerf war training montage! In today's video, Danny shows his epic nerf war training for his big nerf trickshot ...
Die Welt der Online Casinos hat sich in den letzten Jahren rasant entwickelt. online casino paypal bietet. Besonders die Zahlungsmethode PayPal erfreut ...
ContentLeoVegas: welches dritte zuverlässige Spielsaal Online zum Spielen um echtes BaresFunktionen, die Ein Durchgang ...
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback